Your session is about to expire
← Back to Search
Duvelisib + Nivolumab for Advanced Lymphoma
Study Summary
This trial is studying duvelisib and nivolumab to treat Richter syndrome or transformed follicular lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 319 Patients • NCT02004522Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Treatment (duvelisib, nivolumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total enrollment of participants for this trial?
"Unfortunately, this clinical trial has already concluded its recruitment period. The initial posting was on November 5th 2019 and the most recent amendment happened on May 31st 2022. However, those interested in other studies may be pleased to know that there are currently 4130 trials involving leukemia patients actively recruiting as well as 730 research initiatives for Duvelisib."
Has a similar investigation ever been conducted before?
"Since 2012, Duvelisib has been subject to intensive research. Ono Pharmaceutical Co. Ltd sponsored the initial trial in 2012 and enrolled 659 patients for Phase 1 & 2 testing. Currently there are 730 active trials of this drug taking place across 49 countries and 2361 cities worldwide."
Are there any available slots for participants in this experimentation?
"At this time, enrollment for the study has been closed. Initially announced on 11th May 2019 and last amended on 31st May 2022; individuals seeking to actively participate in clinical trials may explore 4130 other studies devoted to treating leukemia or 730 specifically researching Duvelisib."
Has there been any precedent for utilizing Duvelisib in clinical investigations?
"At present, 730 studies are being conducted to assess the efficacy of Duvelisib. Of these investigations, 82 have reached Phase 3 status in clinical trials. Primarily situated in Basel, BE; nevertheless, there exist 40423 other sites also testing this drug's therapeutic potential."
Has Duvelisib been accepted by the FDA for use as a medication?
"With limited data on safety and efficacy, Duvelisib has been scored a 1 for risk level by the Power team."
Could you describe the typical applications of Duvelisib?
"Duvelisib is available to patients with metastatic urothelial carcinoma of the ureter, hepatocellular carcinoma, and malignant melanomas."
Share this study with friends
Copy Link
Messenger